Palatal myoclonus following Behçet's disease ameliorated by ceruletide, a potent analogue of CCK octapeptide.
Systemic administration of ceruletide, a potent analogue of CCK octapeptide (0.8 microgram/kg, i.m.) markedly improved palatal myoclonus. CCK analogues may be useful agents for the treatment of palatal myoclonus. This report suggests that dopaminergic system may also contribute to the underlying biochemical mechanism of palatal myoclonus.
Iwasaki
Y
Y
Fourth Department of Internal Medicine, Toho University Ohashi Hospital, Tokyo, Japan.
Kinoshita
M
M
Ikeda
K
K
Shiojima
T
T
D001528:Behcet Syndrome / Q000188:drug therapy*; D002108:Ceruletide / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000139:chemically induced* / Q000503:physiopathology; D010156:Palatal Muscles / Q000187:drug effects* / Q000503:physiopathology
D002108:Ceruletide